Leuprolide acetate given by a subcutaneous extended-release injection: Less of a pain?

Michael C. Cox, Charity D. Scripture, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Androgen deprivation therapy is a mainstay for the treatment of advanced prostate cancer. Hormonal therapy commonly consists of injection of gonadotropin hormone-releasing hormone agonists. Based on the need for improved convenience of administration, a novel formulation of leuprolide acetate (Eligard®; Atrix Laboratories Inc. & Sanofi Aventis) which incorporates a mixture of selected polymers and solvents to achieve sustained drug delivery after subcutaneous injection, was developed. The US Food and Drug Administration has approved 1-, 3-, 4- and 6-month formulations of leuprolide acetate. In clinical trials, leuprolide acetate achieves sustained suppression of serum testosterone to castration levels (≤50 ng/dl). The adverse-event profile is consistent with the effects of testosterone suppression. This novel delivery system in addition to the availability of a 6-month formulation of leuprolide acetate, offers patients the option of a convenient twice-yearly injection schedule.

Original languageEnglish
Pages (from-to)605-611
Number of pages7
JournalExpert Review of Anticancer Therapy
Issue number4
StatePublished - Aug 2005
Externally publishedYes


  • Androgen
  • Leuprolide acetate
  • Luteinizing hormone
  • Luteinizing hormone-releasing hormone
  • Prostate cancer


Dive into the research topics of 'Leuprolide acetate given by a subcutaneous extended-release injection: Less of a pain?'. Together they form a unique fingerprint.

Cite this